As aprepitant acts as a competitive inhibitor of NK1R [38], high dose treatment with SP should prevent the binding of aprepitant to NK1R, diminishing the treatment effect as previously described for other tumors, including hepatoblastoma [19]. This evidence concerns the gene TACR1 and hepatoblastoma.